Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3769-3775

  Gee, Jason R ^a,b   Burmeister, Corrie B ^b   Havighurst, Thomas C ^c   Kim, Kyungmann ^c  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Bladder cancer; Celecoxib; Chemoprevention; Cyclooxygenase (COX) 2

Indexed keywords

CELECOXIB; CRYSTAL VIOLET; CYCLIN B1; CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2; PHORBOL ESTER; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INDUCTION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; UROGENITAL TRACT CANCER; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN B1; CYCLIN D1; CYCLOOXYGENASE 2; G1 PHASE; HUMANS; PYRAZOLES; RETINOBLASTOMA PROTEIN; SULFONAMIDES; URINARY BLADDER NEOPLASMS;

EID: 71949110045     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Thun MJ, Henley SJ and Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002.
2. Okie S: Raising the safety bar - the FDA's coxib meeting. N Engl J Med 352(13): 1283-1285, 2005.
3. Gee J, Sabichi AL and Grossman HB: Chemoprevention of superficial bladder cancer. Crit Rev Oncol/Hematol 43: 277-288, 2002.
4. White WB, West CR, Borer JS et al: Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 99(1): 91-98, 2007. (Pubitemid 44969347)
5. Bertagnolli MM, Eagle CJ, Zauber AG et al: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9): 873-884, 2006. (Pubitemid 44315980)
6. Dandekar DS, Lopez M, Carey RI and Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 115(3): 484-492, 2005. (Pubitemid 40663755)
7. Altorki NK, Port JL, Zhang F et al: Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 11(11): 4191-4197, 2005. (Pubitemid 40791585)
8. Nugent FW, Mertens WC, Graziano S et al: Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 48(2): 267-273, 2005. (Pubitemid 40501817)
9. Kazanov D, Dvory-Sobol H, Pick M et al: Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Cancer Res 10(1 Pt 1): 267-271, 2004. (Pubitemid 38114189)
10. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S and Kawai S: Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531(2): 278-284, 2002. (Pubitemid 35341208)
11. Waskewich C, Blumenthal RD, Li H et al: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62(7): 2029-2033, 2002. (Pubitemid 34408448)
12. Song X, Lin H-P, Johnson AJ et al: Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94: 585-591, 2002. (Pubitemid 34498645)
13. Johnson AJ, Song X, Hsu A-L, Chen C-S: Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 41: 221-235, 2001. (Pubitemid 32520325)
14. Gee J, Lee I-L, Jendiroba D et al: Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 15(2): 471-477, 2006.
15. Gee JR, Montoya RG, Khaled HM, Sabichi AL and Grossman HB: Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 21(4): 266-270, 2003.
16. DuBois RN, Arbramson SB, Crofford L et al: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998.
17. Mohammed SI, Knapp DW, Bostwick DG et al: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59: 5647-5650, 1999.
18. Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30: 3-21, 2000.
19. Tsujii M, Kawano S, Tsuji S et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998. (Pubitemid 28257578)
20. Tsujii M, Kawano S and Dubois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997. (Pubitemid 27157312)
21. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
22. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081, 2001. (Pubitemid 37411372)
23. Gee J, Lee I-L, Grossman HB and Sabichi AL: Effects of COX-2 overexpression on the immortalized, nontumorigenic urothelial cell line SV-HUC. Urol Oncol 26(6): 641-645, 2008.
24. +-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem Biophys Res Commun 276: 77-81, 2000.
25. Liebert M, Chen I-L, Gebhardt D et al: Loss of expression of prostaglandin dehydrogenase in human bladder cancers. Proc Am Assoc Cancer Res 39: 118, 1998.
26. Gee JR, Chen I-L, Montoya RG et al: Down-regulation of prostaglandin dehydrogenase in invasive transitional cell carcinoma. Proc Am Assoc Cancer Res 42: 264, 2001.
27. Maier TJ, Schilling K, Schmidt R, Geisslinger G and Grosch S: Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67(8): 1469-1478, 2004. (Pubitemid 38388209)
28. Narayanan BA, Condon MS, Bosland MC, Narayanan NK and Reddy BS: Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 9(9): 3503-3513, 2003.
29. Li M, Wu X and Xu XC: Induction of apoptosis by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway in esophageal cancer cells. Int J Cancer 93(2): 218-223, 2001. (Pubitemid 32574278)
30. Leng J, Han C, Demetris AJ, Michalopoulos GK and Wu T: Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 8(3): 756-768, 2003. (Pubitemid 37052162)
31. Hsu AL, Ching TT, Wang DS et al: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275(15): 11397-11403, 2000.
32. Arico S, Pattingre S, Bauvy C et al: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277(31): 27613-27621, 2002. (Pubitemid 34966703)
33. Grossman HB, Wedemeyer G, Ren L, Wilson GN and Cox B: Improved growth of human urothelial carcinoma cell cultures. J Urol 136: 953-959, 1986. (Pubitemid 16026260)
34. Weinstein IB: Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21(5): 857-864, 2000.
35. Cip1/Waf1 on growth and differentiation in human colon carcinoma cells. Oncogene 18(1): 103-115, 1999. (Pubitemid 29060584)
36. Delia D, Goi K, Mizutani S et al: Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene 14(18): 2137-2147, 1997. (Pubitemid 27248225)
37. Williams CS, Watson AJM, Sheng H et al: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res 60: 6045-6051, 2000. (Pubitemid 30839636)
38. Masferrer JL, Leahy KM, Koki AT et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
39. Grubbs CJ, Lubet RA, Koki AT et al: Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60(20): 5599-5602, 2000.
40. Tegeder I, Pfeilschifter J and Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15: 2058-2072, 2001.